EWTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Edgewise Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$37.92+0.73 (+1.96%)

Close on Oct 19, 2026

Market cap: $4.08B
P/E (TTM): –
Dividend yield: –

Edgewise Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Research & Development	151	127	91	54	32	15
General & Administrative	40	32	23	18	11	2.21
Operating Expenses	191	159	114	72	43	17
Operating Income	-191	-159	-114	-72	-43	-17
Interest & Investment Income	24	25	14	4.02	0.40	0.07
Asset Impairment Charges	0	0	0	0	0	0
Pretax Income	-168	-134	-100	–	–	–
Income Tax Expense	0.00	0.00	0.00	0	0	–
Net Income incl. Noncontrolling Interests	-168	-134	-100	-68	-43	-17
Net Income	-168	-134	-100	-68	-43	-17
EPS (Basic)(per share)	-1.63	-1.45	-1.57	-1.26	-1.14	-23.17
EPS (Diluted)(per share)	-1.63	-1.45	-1.57	-1.26	-1.14	-23.17
Shares Outstanding (Basic, Weighted)(shares)	103	92	64	54	38	0.74
Shares Outstanding (Diluted, Weighted)(shares)	103	92	64	54	38	0.74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -34.2%

Financial strength

Current ratio: 16.24
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 249.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 9.11
Dividend yield: –